osimertinib
AstraZeneca Sees New Lung Cancer Indication for Tagrisso, Chemo in FLAURA2 Data
Based on high-level results from the trial, the firm believes the combination could be a new first-line option for patients with advanced EGFR-mutated NSCLC.
AstraZeneca Oncology Rx Sales Grow 19 Percent in Q1 as Execs Lay Out Expansion Plans in Lung Cancer
Premium
By 2030, the firm is planning to develop new treatments that 50 percent of lung cancer patients will be eligible for.
EGFR-Mutant NSCLC Patients See Similar Survival in Upfront Tagrisso Versus Sequential Treatment
Premium
A new analysis from the Phase II APPLE trial showed minimal differences in overall survival, though the newer generation TKI significantly reduced brain metastases.
The firm looks forward to launching new trials in 2023 and building out its breast and lung cancer treatment portfolios.
Theseus Pharmaceuticals to Develop Pan-EGFR Inhibitor for Resistant NSCLC Patients
The firm plans to submit an IND during the second half 2023 for the investigational drug, which is designed to overcome EGFR-targeted treatment resistance.
Aug 11, 2022
Feb 10, 2022
AstraZeneca Q4 Oncology Revenues Grow 20 percent
Nov 12, 2021
AstraZeneca's Q3 Oncology Revenues Grow 18 Percent
Jul 29, 2021